Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Saquinavir (Invirase, SQV)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 8
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
Note: Must be combined with low-dose RTV for PK boosting.
|Standard Adult Dose:
PK in Pregnancy:
Dosing in Pregnancy:
|SQV should not be used during pregnancy.
Contraindicated in patients with pre-existing cardiac conduction system disease. Baseline ECG recommended before starting, because PR and/or QT interval prolongations have been observed.
Low placental transfer to fetus.b
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
Must be boosted with low-dose RTV.
a Individual antiretroviral drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
Key to Acronyms: ECG = electrocardiogram; PK = pharmacokinetic; RTV = ritonavir; SQV = saquinavir
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive